Cargando…

Postoperative IMRT in head and neck cancer

BACKGROUND: Aim of this work was to assess loco-regional disease control in head and neck cancer (HNC) patients treated with postoperative intensity modulated radiation therapy (pIMRT). For comparative purposes, risk features of our series have been analysed with respect to histopathologic adverse f...

Descripción completa

Detalles Bibliográficos
Autores principales: Studer, Gabriela, Furrer, Katrin, Davis, Bernard J, Stoeckli, Sandro S, Zwahlen, Roger A, Luetolf, Urs M, Glanzmann, Christoph
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1626476/
https://www.ncbi.nlm.nih.gov/pubmed/17052346
http://dx.doi.org/10.1186/1748-717X-1-40
_version_ 1782130606498381824
author Studer, Gabriela
Furrer, Katrin
Davis, Bernard J
Stoeckli, Sandro S
Zwahlen, Roger A
Luetolf, Urs M
Glanzmann, Christoph
author_facet Studer, Gabriela
Furrer, Katrin
Davis, Bernard J
Stoeckli, Sandro S
Zwahlen, Roger A
Luetolf, Urs M
Glanzmann, Christoph
author_sort Studer, Gabriela
collection PubMed
description BACKGROUND: Aim of this work was to assess loco-regional disease control in head and neck cancer (HNC) patients treated with postoperative intensity modulated radiation therapy (pIMRT). For comparative purposes, risk features of our series have been analysed with respect to histopathologic adverse factors. Results were compared with an own historic conventional radiation (3DCRT) series, and with 3DCRT and pIMRT data from other centres. Between January 2002 and August 2006, 71 patients were consecutively treated with pIMRT for a squamous cell carcinoma (SCC) of the oropharynx (32), oral cavity (22), hypopharynx (7), larynx (6), paranasal sinus (3), and an unknown primary, respectively. Mean and median follow up was 19 months (2–48), and 17.6 months. 83% were treated with IMRT-chemotherapy. Mean prescribed dose was 66.3 Gy (60–70), delivered with doses per fraction of 2–2.3 Gy, respectively. RESULTS: 2-year local, nodal, and distant control rates were 95%, 91%, and 96%, disease free and overall survival 90% and 83%, respectively. The corresponding survival rates for the subgroup of patients with a follow up time >12 months (n = 43) were 98%, 95%, 98%, 93%, and 88%, respectively. Distribution according to histopathologic risk features revealed 15% and 85% patients with intermediate and high risk, respectively. All loco-regional events occurred in the high risk subgroup. CONCLUSION: Surgery followed by postoperative IMRT in patients with substantial risk for recurrence resulted in high loco-regional tumor control rates compared with large prospective 3DCRT trials.
format Text
id pubmed-1626476
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-16264762006-10-28 Postoperative IMRT in head and neck cancer Studer, Gabriela Furrer, Katrin Davis, Bernard J Stoeckli, Sandro S Zwahlen, Roger A Luetolf, Urs M Glanzmann, Christoph Radiat Oncol Research BACKGROUND: Aim of this work was to assess loco-regional disease control in head and neck cancer (HNC) patients treated with postoperative intensity modulated radiation therapy (pIMRT). For comparative purposes, risk features of our series have been analysed with respect to histopathologic adverse factors. Results were compared with an own historic conventional radiation (3DCRT) series, and with 3DCRT and pIMRT data from other centres. Between January 2002 and August 2006, 71 patients were consecutively treated with pIMRT for a squamous cell carcinoma (SCC) of the oropharynx (32), oral cavity (22), hypopharynx (7), larynx (6), paranasal sinus (3), and an unknown primary, respectively. Mean and median follow up was 19 months (2–48), and 17.6 months. 83% were treated with IMRT-chemotherapy. Mean prescribed dose was 66.3 Gy (60–70), delivered with doses per fraction of 2–2.3 Gy, respectively. RESULTS: 2-year local, nodal, and distant control rates were 95%, 91%, and 96%, disease free and overall survival 90% and 83%, respectively. The corresponding survival rates for the subgroup of patients with a follow up time >12 months (n = 43) were 98%, 95%, 98%, 93%, and 88%, respectively. Distribution according to histopathologic risk features revealed 15% and 85% patients with intermediate and high risk, respectively. All loco-regional events occurred in the high risk subgroup. CONCLUSION: Surgery followed by postoperative IMRT in patients with substantial risk for recurrence resulted in high loco-regional tumor control rates compared with large prospective 3DCRT trials. BioMed Central 2006-10-19 /pmc/articles/PMC1626476/ /pubmed/17052346 http://dx.doi.org/10.1186/1748-717X-1-40 Text en Copyright © 2006 Studer et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Studer, Gabriela
Furrer, Katrin
Davis, Bernard J
Stoeckli, Sandro S
Zwahlen, Roger A
Luetolf, Urs M
Glanzmann, Christoph
Postoperative IMRT in head and neck cancer
title Postoperative IMRT in head and neck cancer
title_full Postoperative IMRT in head and neck cancer
title_fullStr Postoperative IMRT in head and neck cancer
title_full_unstemmed Postoperative IMRT in head and neck cancer
title_short Postoperative IMRT in head and neck cancer
title_sort postoperative imrt in head and neck cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1626476/
https://www.ncbi.nlm.nih.gov/pubmed/17052346
http://dx.doi.org/10.1186/1748-717X-1-40
work_keys_str_mv AT studergabriela postoperativeimrtinheadandneckcancer
AT furrerkatrin postoperativeimrtinheadandneckcancer
AT davisbernardj postoperativeimrtinheadandneckcancer
AT stoecklisandros postoperativeimrtinheadandneckcancer
AT zwahlenrogera postoperativeimrtinheadandneckcancer
AT luetolfursm postoperativeimrtinheadandneckcancer
AT glanzmannchristoph postoperativeimrtinheadandneckcancer